Thionucleotides Concept

Vocabulary Service

MeSH

Overview

subject area of

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer Journal Articles
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798) Journal Articles
Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis. Journal Articles
Chemosensitization of gemcitabine‐resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti‐apoptotic gene, clusterin Journal Articles
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy Journal Articles
Crystal structure of cGMP‐dependent protein kinase Iβ cyclic nucleotide‐binding‐B domain : Rp‐cGMPS complex reveals an apo‐like, inactive conformation Journal Articles
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial Journal Articles
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial Journal Articles
Effect of gamma-thio-ATP on dog stomach smooth muscle membranes. Journal Articles
Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation Journal Articles
MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma Journal Articles
Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer Journal Articles
Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma Journal Articles
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆ Journal Articles
Purinergic stimulation of astroblast proliferation: Guanosine and its nucleotides stimulate cell division in chick astroblasts Journal Articles
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer Conferences
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c Journal Articles
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsen Journal Articles